Clinical trials: Squamous Non-small-cell Lung Cancer
Breast Cancer, Colorectal Cancer
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
This pilot, non-interventional, observational, Web-based, prospective cohort study is designed to collect self-reported safety and effectiveness and genetic data from subjects with locally recurrent breast cancer (BC) or…
- Conditions
- Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma
- Trial name
- NCT01598597
- Where
- 50 sites in United States
- Volunteers
- 276 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
NSCLC, HNSCC
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
- Trial name
- TACTI-002 (NCT03625323)
- Testing
- eftilagimod alpha, pembrolizumab (KEYTRUDA®)
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Immutep S.A.S.
Non-Squamous Non-Small Cell Neoplasm of Lung
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with…
- Trial name
- DOMAJOR (NCT03912389)
- Testing
- BCD-100, Pemetrexed, Cisplatin (or carboplatin)
- Where
- 37 sites in Czechia, Georgia and 4 more
- Volunteers
- 292 people
- Sponsor
- Biocad
Non-small-cell Lung Cancer
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
The primary objective of this study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival (OS) compared to erlotinib monotherapy in subjects with locally advanced or metastatic…
- Trial name
- ATTENTION (NCT01377376)
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Sponsor
- Kyowa Kirin Co., Ltd.
Non-squamous Non-small-cell Lung Cancer, Anlotinib
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. The ALTER-0303 trial showed that patients with advanced non-small cell lung cancer (NSCLC) who received…
- Trial name
- NCT04012619
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Sichuan University
Advanced Non-squamous Non-Small-Cell Lung Cancer
First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial
To evaluate the efficacy and safety of sintilimab plus bevacizumab and platinum-based doublet chemotherapy as the first-line therapy for advanced nonsquamous non-small-cell lung cancer(NSCLC) with negative driver gene.
- Trial name
- SPBPDC (NCT05648071)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qianfoshan Hospital
Lung Cancer
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00863512
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 94 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of…
- Conditions
- Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00596830
- Testing
- CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
- Where
- 280 sites in United States, Australia and 24 more
- Volunteers
- 681 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
NSCLC is the most common type of lung cancer. Metastatic cancers are cancers that start to spread to other parts of the body. NSCLC is treated by radiation therapy, with medicines, surgery, or immunotherapy.
- Trial name
- Lotus (NCT06643117)
- Testing
- FYB206, Keytruda
- Where
- 13 sites in Georgia, Malaysia and 1 more
- Volunteers
- 25 people
- Sponsor
- Formycon AG
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
- Trial name
- NCT03847519
- Testing
- ADXS-503, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Advaxis, Inc.
Advanced Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with…
- Trial name
- NCT02554812
- Testing
- Avelumab, Utomilumab, PF-04518600
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 409 people
- Sponsor
- Pfizer
Lung Neoplasms
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Efficacy and Safety Evaluation of IBI308 in Patients with advanced or metastatic Non-squamous NSCLC
- Trial name
- NCT03607539
- Testing
- Sintilimab, Pemetrexed, Platinum
- Where
- China
- Volunteers
- 397 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Lung Cancer
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of onartuzumab that can be given with erlotinib and standard chemoradiation (paclitaxel and carboplatin) to patients with NSCLC.
- Trial name
- NCT02044601
- Testing
- Onartuzumab, Erlotinib, Paclitaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01041781
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 400 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alliance for Clinical Trials in Oncology